Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.37 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 5/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | HTR7 | P34969 | 3/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14412163 | 1.00 | PDE10A (0.39) | PDE10ADRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL14412182 | 0.93 | PDE10A (0.43) | PDE10APTPN7CNR2 | |
| SCHEMBL5452072 | 0.93 | PDE10A (0.43) | PDE10APTPN7CNR2 | |
| SCHEMBL14412171 | 0.91 | PDE10A (0.37) | PDE10ADRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL5444135 | 0.91 | PDE10A (0.37) | PDE10ADRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL14412071 | 0.91 | PDE10A (0.39) | PDE10ADRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL5450959 | 0.91 | PDE10A (0.39) | PDE10ADRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL5448149 | 0.88 | MET (0.40) | PDE10APTPN7CNR2 | |
| SCHEMBL5444386 | 0.88 | PDE10A (0.50) | PDE10APTPN7CNR2 | |
| SCHEMBL14412091 | 0.88 | PDE10A (0.50) | PDE10APTPN7CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | PDE10A 514/4885DRD2 2688/4885ADRA1D 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.